Shots:

• Sanofi will provide its S-protein COVID-19 antigen- based on recombinant DNA technology. The technology that produces an exact genetic match to proteins found on the surface of the virus and the DNA sequence encoding the antigen is combined into the DNA of the baculovirus expression platform
• GSK will deploy its adjuvant technology as the use of it can reduce the amount of vaccine protein required/ dose- allowing more vaccine doses to be produced- thus contributing to protecting more people amid a pandemic
• The companies plan to commence the P-I clinical study in H2’20 with a goal to complete the development required for availability by H2’21. Both the companies are in discussion with governments and global institution for funding and have set-up a Joint Task Force- which will seek to mobilize resources from both companies in order to facilitate the development of vaccine candidates

Click here to­ read full press release/ article 

Ref: Sanofi | Image: Sanofi